2.2.0.25falsefalse0213 - Disclosure - Subsequent eventstruefalsefalse1falsefalseUSDfalsefalse1/1/2011 - 3/31/2011
USD ($)
USD ($) / shares
$Jan-01-2011_Mar-31-2011http://www.sec.gov/CIK0000318154duration2011-01-01T00:00:002011-03-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0amgn_SubsequentEventsAbstractamgnfalsenadurationSubsequent events.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSubsequent events.falsefalse3false0us-gaap_ScheduleOfSubsequentEventsTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 13 - us-gaap:ScheduleOfSubsequentEventsTextBlock-->
<div style="font-family: 'Times New Roman',Times,serif">
<div align="left" style="font-size: 10pt; margin-top: 10pt"><b>13. Subsequent events</b>
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In April 2011, we announced our acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda
(Bergamo), a privately-held Brazilian pharmaceutical company, for approximately $215 million in
cash. Bergamo is a leading supplier of medicines to the hospital sector in Brazil with capabilities
in oncology medicines. The company has approximately 400 staff, a portfolio of marketed products
and manufacturing facilities in the state of Sao Paulo, Brazil. Upon its acquisition, Bergamo
became a wholly owned subsidiary of Amgen. This acquisition will provide us with direct access to
the Brazilian pharmaceutical market. This transaction will be accounted for as a business
combination and included in our condensed consolidated financial statements commencing on the
acquisition date.
</div>
<div align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Pro forma supplemental condensed consolidated financial information for Amgen including the
results of Bergamo assuming an acquisition date of January 1, 2011 and 2010 is not provided as the
impact to our condensed consolidated results of operations would not be material, either
individually or when aggregated with the acquisition of BioVex (see Note 2, Acquisitions).
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes disclosed significant events or transactions that occurred after the balance sheet date, but before the issuance of the financial statements. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 11
falsefalse12Subsequent eventsUnKnownUnKnownUnKnownUnKnownfalsetrue